Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Daxibotulinumtoxin A
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirsram Medical Announces NMPA Approval for DAXXIFY
Details : Daxxify (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor for temporary improvement in the appearance of moderate to severe glabellar line in adult patients.
Product Name : Daxxify
Product Type : Protein
Upfront Cash : Inapplicable
September 09, 2024
Lead Product(s) : Daxibotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable